Related Experiment Video
Updated: Jun 25, 2026
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
ReFerm® a Fermented Oat Gruel Composition, Improves Colonic Barrier Function and Modulates Tricellulin Expression in
Vittorio Abruzzese1, Olga Biskou1, Martin E Winberg1
1Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Background:
Intestinal barrier dysfunction has been implicated in the pathophysiology of irritable bowel syndrome (IBS), contributing to increased permeability, low-grade inflammation, and symptom generation. Microbial compositions are known to improve epithelial barrier function, although the underlying molecular mechanisms remain elusive. The aim was to investigate the effects of the fermented oat gruel preparation ReFerm® on colonic barrier function and tight junction protein expressions in patients with IBS.
Methods:
Colonic biopsies from patients with IBS were mounted in Ussing chambers to assess the direct effects of ReFerm® on epithelial permeability. In parallel, biopsies from patients treated with ReFerm® or placebo by enema were analyzed for the expression of multiple tight junction proteins using Western blotting and confocal microscopy. In vitro effects were further evaluated in Caco-2 cells.
Key Results:
ReFerm® reduced both paracellular and transcellular permeability when added directly to biopsies mounted in Ussing chambers, compared with unstimulated biopsies. This effect was accompanied by increased expression of the tight junction protein tricellulin at tricellular junctions. In vitro experiments in Caco-2 cells supported these findings, demonstrating direct effects of ReFerm® on epithelial barrier properties.
Conclusions And Interferences:
ReFerm® strengthens colonic barrier integrity in the gut mucosa of patients with IBS, potentially through modulation of the tight junction protein tricellulin. These findings provide mechanistic insight into the barrier-protective effects of fermented oat interventions such as ReFerm® and support the potential therapeutic role in IBS.
Related Concept Videos
01:23Irritable Bowel Syndrome
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS